Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05452382
Other study ID # NCDBAppendix
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1, 2005
Est. completion date July 6, 2022

Study information

Verified date July 2022
Source Mansoura University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

A few studies investigated the predictors of overall survival in appendiceal adenocarcinoma. A SEER database analysis of 1404 patients with appendiceal adenocarcinoma found that older age, T4 tumors, N1-2 stage, poorly differentiated carcinoma, and distant metastasis were significantly predictive of poorer survival. Another small single-center study including 49 appendiceal cancer patients reported female gender and low-grade adenocarcinoma to be associated with increased overall survival. However, these previous analyses did not take into account some important prognosticators of survival such as patients' comorbidities and functional status, pathologic parameters such as lymphovascular invasion, and adjuvant systemic treatment. Therefore, we used the National Cancer Database (NCDB) to conduct a comprehensive analysis of the predictors of overall survival after surgical treatment of stage I-III appendiceal adenocarcinoma.


Recruitment information / eligibility

Status Completed
Enrollment 2607
Est. completion date July 6, 2022
Est. primary completion date December 30, 2019
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - patients with non-metastatic appendiceal adenocarcinoma who underwent surgical resection Exclusion Criteria: - Patients with other pathologic types of appendiceal cancer - Patients with clinical stage IV or unknown stage - Patients who did not undergo surgery, underwent local excision, or had unknown/non-specified surgery

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Partial colecctomy
Segmental resection of appendiceal adenocarcinoma including terminal ileum and cecum
Hemicolectomy
Formal right hemicolectomy including terminal ileum, cecum, and ascending colon

Locations

Country Name City State
United States Cleveland Clinic Flroida Weston Florida

Sponsors (2)

Lead Sponsor Collaborator
Mansoura University Cleveland Clinic Florida

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall survival Percent of patients who were alive at five years of follow-up 60 months
Secondary Positive resection margins the rate of surgical margins infiltrated by malignancy Immediate postoperative
See also
  Status Clinical Trial Phase
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT06101277 - Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG) N/A
Recruiting NCT04847063 - Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies Phase 1
Recruiting NCT05185947 - Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer Phase 2
Completed NCT02040142 - Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C Phase 2
Recruiting NCT05734430 - Genetics of Appendix Cancer Study
Completed NCT03604653 - Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers
Terminated NCT04158349 - Intraperitoneal Oxaliplatin in Combo w IV mFOLFIRI for Peritoneal Carcinomatosis From Colorectal & Appendiceal Cancer Phase 1
Not yet recruiting NCT05364788 - Molecular Characterisation of Appendiceal Cancer
Recruiting NCT05194995 - JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation Phase 1/Phase 2